Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0
|
作者：
Bartlett, Nancy L. [1 ]
Sehn, Laurie H. [2 ,3 ]
Matasar, Matthew [4 ]
Schuster, Stephen J. [5 ]
Assouline, Sarit [6 ]
Giri, Pratyush [7 ]
Kuruvilla, John [8 ]
Canales, Miguel [9 ]
Dietrich, Sascha [10 ]
Fay, Keith [11 ,12 ]
Ku, Matthew [13 ]
Nastoupil, Loretta [14 ]
Wei, Michael C. [15 ]
Yin, Shen [15 ]
To, Iris [15 ]
Huang, Huang [16 ]
Min, Juliana [17 ]
Bolen, Christopher R. [15 ]
Penuel, Elicia [15 ]
Budde, L. Elizabeth [18 ]
机构：
[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA
[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA
[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[7] Royal Adelaide Hosp, Adelaide, SA, Australia
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Hosp Univ La Paz, Madrid, Spain
[10] Heidelberg Univ, Heidelberg, Germany
[11] St Vincents Hosp, Sydney, NSW, Australia
[12] Royal North Shore Hosp, Sydney, NSW, Australia
[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia
[14] MD Anderson Canc Ctr, Houston, TX USA
[15] Genentech Inc, San Francisco, CA USA
[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[17] Roche Prod Ltd, Welwyn Garden City, Herts, England
[18] City Hope Natl Med Ctr, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-458
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [11] ePharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
    Huw, Ling-Yuh
    Li, Feifei
    Belousov, Anton
    Ramesha, Hemanth
    Bolen, Christopher R.
    Wei, Michael C.
    Yin, Shen
    Turner, David C.
    Penuel, Elicia
    BLOOD, 2022, 140 : 6448 - 6449
  • [12] Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
    Wang, Michael L.
    Assouline, Sarit
    Kamdar, Manali
    Ghosh, Nilanjan
    Naik, Seema
    Nakhoda, Shazia K.
    Chavez, Julio C.
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Jing, Jing
    Ead, Wahib
    To, Iris
    Batlevi, Connie Lee
    Wei, Michael C.
    Budde, L. Elizabeth
    BLOOD, 2023, 142
  • [13] Mosunetuzumab Monotherapy is an effective and well-tolerated Treatment Option in Patients with relapsed/refractory follicular Lymphoma who have previously received plus or minus 2 Lines of Therapy: Key Results from a Phase I/II Study
    Hess, G.
    Budde, L. E.
    Sehn, L. H.
    Matasar, M.
    Schuster, S. J.
    Assouline, S.
    Giri, P.
    Kuruvilla, J.
    Canales, M.
    Dietrich, S.
    Fay, K.
    Ku, M.
    Nastoupil, L.
    Wei, M. C.
    Yin, S.
    Doral, M. Y.
    Li, C. -C.
    Huang, H.
    Negricea, R.
    Penuel, E.
    O'Hear, C.
    Bartlett, N. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 148 - 148
  • [14] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
    Budde, Lihua E.
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Cheah, Chan Yoon
    Wei, Michael C.
    Yin, Shen
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Bartlett, Nancy L.
    LANCET ONCOLOGY, 2022, 23 (08): : 1055 - 1065
  • [15] Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Thomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S435
  • [16] Glofitamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma and ≥2 Prior Therapies: Results from a Pivotal Phase II Expansion Study
    Michael, Dickinson
    Carmelo, Carlo-Stella
    Franck, Morschhauser
    Emmanuel, Bachy
    Paolo, Corradini
    Gloria, Iacoboni
    Cyrus, Khan
    Tomasz, Wrobel
    Fritz, Offner
    Marek, Trneny
    Shang-Ju, Wu
    Guillaume, Cartron
    Mark, Hertzberg
    Anna, Sureda
    David, Perez-Callejo
    Linda, Lundberg
    James, Relf
    Emma, Clark
    Kathryn, Humphrey
    Martin, Hutchings
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S39 - S40
  • [17] Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥ 2 Prior Therapies
    Song, Yu-Qin
    Zhang, Hui-Lai
    Huang, Hui-Qiang
    Zhang, Qing-Yuan
    Jing, Hong-Mei
    Wang, Chao
    Wu, Chun
    Li, Dong-Hang
    Dai, Yu
    Humphrey, Kathryn
    Zhu, Jun
    BLOOD, 2022, 140 : 12050 - 12051
  • [18] Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
    Armand, Philippe
    Janssens, Ann
    Gritti, Giuseppe
    Radford, John
    Timmerman, John
    Pinto, Antonio
    Vilchez, Santiago Mercadal
    Johnson, Peter
    Cunningham, David
    Leonard, John P.
    Rodig, Scott J.
    Martin-Regueira, Patricia
    Sumbul, Anne
    Samakoglu, Selda
    Tang, Hao
    Ansell, Stephen M.
    BLOOD, 2021, 137 (05) : 637 - 645
  • [19] YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
    Barba, Pere
    Kwon, Mi
    Briones, Javier
    Jaeger, Ulrich
    Bachy, Emmanuel
    Blaise, Didier
    Boissel, Nicolas
    Kato, Koji
    Shah, Nirav N.
    Frigault, Matthew
    Riedell, Peter A.
    Shune, Leyla O.
    Teshima, Takanori
    Ciceri, Fabio
    Pearson, David
    Orlando, Elena J.
    Yi, Lan
    Davis, Jaclyn
    Masood, Aisha
    Flinn, Ian W.
    Dickinson, Michael
    BLOOD, 2022, 140 : 1056 - 1059
  • [20] Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study
    Flinn, Ian W.
    Budde, L. Elizabeth
    Tun, Aung M.
    Burke, John M.
    Anz, Bertrand
    Peles, Shachar
    Sharman, Jeff P.
    Tumula, Praveen K.
    Biondo, Juliana M. L.
    Jani, Prachi
    Wu, Mei
    Lin, Tony
    Parmar, Neha
    Mun, Yong
    Yao, Nai-Shun
    Liu, Steven
    BLOOD, 2023, 142
12345